Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 300-1351 RUE Notre-Dame E THETFORD MINES QC G6G 0G5 |
Tel: | N/A |
Website: | www.alliancepharma.ca |
IR: | See website |
Key People | ||
Marc Lemieux Chairman of the Board, President, Chief Executive Officer | Isabelle Begin Executive Vice President, Director |
Business Overview |
KDA Group Inc. is a Canada-based solution and services provider to pharmacies and pharmaceutical companies in Canada as well as technological platform for the health industry. The Company's segments include Pharmacy Services, Pharmaceutical Solutions and Pharmaceutical Technology. Its Pharmacy Services segment offers training, consulting, and replacement services for professional resources in the field of healthcare. Its Pharmaceutical Solutions segment is engaged in the development and integration of technological platforms dedicated to all healthcare professionals. Its Pharmaceutical technology segment offers KRX, KRX DENTAL and ADRX platforms. It also offers ZRx Digital Prescriber an electronic prescriber computer and mobile software designed and developed for use by healthcare providers who are authorized to prescribe medications and other treatments. Its subsidiaries include Alliance Pharma Operations Inc., Elitis Pharma Inc., Logistik Pharma Inc. and Groupe Technologique KDA Inc. |
Financial Overview |
For the six months ended 31 January 2024, KDA Group Inc revenues increased 27% to C$118K. Net loss before extraordinary items increased 18% to C$2.7M. Revenues reflect Corporate and others segment increase from C$1K to C$108K. Higher net loss reflects Amortization and depreciation increase from C$154K to C$814K (expense), Loss on disposal of preferred shares increase from C$0K to C$325K (expense). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $72.10M as of Jan 31, 2024 |
Annual revenue (TTM): | $0.19M as of Jan 31, 2024 |
EBITDA (TTM): | -$3.37M as of Jan 31, 2024 |
Net annual income (TTM): | $0.13M as of Jan 31, 2024 |
Free cash flow (TTM): | -$5.03M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 175,315,947 as of Mar 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |